About RiverTown Therapeutics
RiverTown Therapeutics, Inc (RTI) is a clinical stage biopharmaceutical company committed to reversing androgenic alopecia (also known as male pattern baldness) using our core platform, and lead topical compound, RT1640.
By any definition, androgenic alopecia (AGA) is an unmet medical need, with over 90 million men and women affected in the US alone. The current available treatments for AGA are at best, partially effective, with some having serious potential side effects. Even with the limited treatment choices now available, the US market for hair restoration is estimated at $4B, with no dominant company. In spite of the size of the market, there is currently no single dominant company.
A 2014 paper in the journal Expert Opinion on Therapeutic Targets stated: “It is unlikely that single targeted agents will be sufficient for treating AGA, and therefore, it would be a challenge to obtain compounds with multiple activities”
The RTI scientific founder, David E. Weinstein, MD, PhD reached a similar conclusion. To overcome this hurdle, he developed RT1640, which consists of three active agents formulated for twice daily application. The three drugs synergize to promote the recruitment of new hair follicles, and/or rejuvenate existing follicles that have become dormant, a normal event in AGA. 100% of the subjects treated to date with RT1640 have responded with robust hair growth, and in several instances, complete restoration of the hair. Unlike other treatments on the market, RT1640 is effective in both men and women, irrespective of age or the duration of hair loss.